Definium Therapeutics is trading at $37.84, up 4.60% during the September 28, 2026 session, with no fresh company-specific announcement identified to explain the rise.
- The latest major company news identified was positive Phase 3 Panorama results announced September 14; that news does not establish the cause of this session’s rise.
- The supplied market context is negative and does not explain the stock’s move higher.
- Intraday volume or activity level is unavailable in the provided price context.